Ritu Roy

Ritu Roy

Auto-generated profile, based on publicly available information

Ritu Roy

Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, USA

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 February 2017 in Clinical Epigenetics
Verified
Journal Article
Open access
PDF file
JWJohn K. Wiencke
John K. Wiencke
DKDevin C Koestler
Devin C Koestler
LSLucas A Salas
Lucas A Salas
JWJoseph L. Wiemels
Joseph L. Wiemels
RRRitu P. Roy
Ritu P. Roy
BCBrock C. Christensen
Brock C. Christensen
Differentially methylated regions (DMRs) within DNA isolated from whole blood can be used to estimate the proportions of circulating leukocyte subtypes. We use the term “immunomethylomics” to describe the application of these immune lineage DMRs to studying leukocyte profiles. Here, we applied this approach to peripheral blood DNA from 72 glioma patients with molecularly defined brain tumors, representing common patient groups with defined characteristic survival times and risk factors. We first estimated the proportions of leukocyte subtypes in samples using deconvolution algorithms with reference DMR libraries from isolated leukocyte populations and Illumina 450K DNA methylation data. Then, we calculated the neutrophil to lymphocyte ratio (NLR) using methylation-derived cell composition estimates (mdNLR). The NLR is considered an indicator of immunosuppressive cells in cancer patients. Elevated mdNLR scores were observed in glioma patients compared to mdNLR values of published controls. Significantly decreased survival times were associated with mdNLR ≥ 4.0 in Cox proportional hazards models adjusted for age, gender, tumor grade, and molecular subtype (HR 2.02, 95% CI, 1.11–3.69). We also identified five myeloid-related CpGs that were highly correlated with the mdNLR (adjusted R 2 ≥ 0.80). Each of the five myeloid CpG loci was associated with survival when adjusted for the above covariates and offer a simplified approach for utilizing fresh or archived peripheral blood samples for interrogating a very small number of methylation markers to estimate myeloid immune influences in glioma survival. The mdNLR (based on DNA methylation) is a novel candidate methylation biomarker that represents immunosuppressive myeloid cells within the blood of glioma patients with potential application in clinical trials and future epidemiologic studies of glioma risk and survival.

22 October 2021 in JCI Insight
Verified
Journal Article
Open access
PDF file
MBMehdi Bouhaddou
Mehdi Bouhaddou
RLRex H. Lee
Rex H. Lee
HLHua Li
Hua Li
NBNeil E. Bhola
Neil E. Bhola
RORachel A. O’KEefe
Rachel A. O’KEefe
JGJennifer Grandis
Jennifer Grandis
The epidermal growth factor receptor (EGFR) inhibitor cetuximab is the only FDA-approved oncogene-targeting therapy for head and neck squamous cell carcinoma (HNSCC). Despite variable treatment response, no biomarkers exist to stratify patients for cetuximab therapy in HNSCC. Here, we applied unbiased hierarchical clustering to reverse-phase protein array molecular profiles from patient-derived xenograft (PDX) tumors and revealed 2 PDX clusters defined by protein networks associated with EGFR inhibitor resistance. In vivo validation revealed unbiased clustering to classify PDX tumors according to cetuximab response with 88% accuracy. Next, a support vector machine classifier algorithm identified a minimalist biomarker signature consisting of 8 proteins — caveolin-1, Sox-2, AXL, STING, Brd4, claudin-7, connexin-43, and fibronectin — with expression that strongly predicted cetuximab response in PDXs using either protein or mRNA. A combination of caveolin-1 and Sox-2 protein levels was sufficient to maintain high predictive accuracy, which we validated in tumor samples from patients with HNSCC with known clinical response to cetuximab. These results support further investigation into the combined use of caveolin-1 and Sox-2 as predictive biomarkers for cetuximab response in the clinic.

18 September 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
CPCheryl A. C. Peretz
Cheryl A. C. Peretz
VKVanessa E. Kennedy
Vanessa E. Kennedy
AWAnushka Walia
Anushka Walia
CDCyrille L. Delley
Cyrille L. Delley
AKAndrew Koh
Andrew Koh
CSCatherine C. Smith
Catherine C. Smith
Despite recent work linking mixed phenotype acute leukemia (MPAL) to certain genetic lesions, specific driver mutations remain undefined for a significant proportion of patients and no genetic subtype is predictive of clinical outcomes. Moreover, therapeutic strategy for MPAL remains unclear, and prognosis is overall poor. We performed multiomic single cell profiling of 14 newly diagnosed adult MPAL patients to characterize the inter- and intra-tumoral transcriptional, immunophenotypic, and genetic landscapes of MPAL. We show that neither genetic profile nor transcriptome reliably correlate with specific MPAL immunophenotypes. Despite this, we find that MPAL blasts express a shared stem cell-like transcriptional profile indicative of high differentiation potential. Patients with the highest differentiation potential demonstrate inferior survival in our dataset. A gene set score, MPAL95, derived from genes highly enriched in the most stem-like MPAL cells, is applicable to bulk RNA sequencing data and is predictive of survival in an independent patient cohort, suggesting a potential strategy for clinical risk stratification.

1 December 2017 in Translational Oncology
Verified
Journal Article
Open access
AAAdam Autry
Adam Autry
JPJoanna J. Phillips
Joanna J. Phillips
SMStojan Maleschlijski
Stojan Maleschlijski
RRRitu Roy
Ritu Roy
AMAnnette M. Molinaro
Annette M. Molinaro
SNSarah J. Nelson
Sarah J. Nelson
Although the contrast-enhancing (CE) lesion on T1-weighted MR images is widely used as a surrogate for glioblastoma (GBM), there are also non-enhancing regions of infiltrative tumor within the T2-weighted lesion, which elude radiologic detection. Because non-enhancing GBM (Enh-) challenges clinical patient management as latent disease, this study sought to characterize ex vivo metabolic profiles from Enh- and CE GBM (Enh+) samples, alongside histological and in vivo MR parameters, to assist in defining criteria for estimating total tumor burden. Fifty-six patients with newly diagnosed GBM received a multi-parametric pre-surgical MR examination. Targets for obtaining image-guided tissue samples were defined based on in vivo parameters that were suspicious for tumor. The actual location from where tissue samples were obtained was recorded, and half of each sample was analyzed for histopathology while the other half was scanned using HR-MAS spectroscopy. The Enh+ and Enh- tumor samples demonstrated comparable mitotic activity, but also significant heterogeneity in microvascular morphology. Ex vivo spectroscopic parameters indicated similar levels of total choline and N-acetylaspartate between these contrast-based radiographic subtypes of GBM, and characteristic differences in the levels of myo-inositol, creatine/phosphocreatine, and phosphoethanolamine. Analysis of in vivo parameters at the sample locations were consistent with histological and ex vivo metabolic data. The similarity between ex vivo levels of choline and NAA, and between in vivo levels of choline, NAA and nADC in Enh+ and Enh- tumor, indicate that these parameters can be used in defining non-invasive metrics of total tumor burden for patients with GBM.

2 January 2021 in Fatigue: Biomedicine, Health & Behavior
Verified
Journal Article
Open access
KKKord M. Kober
Kord M. Kober
RRRitu Roy
Ritu Roy
ADAnand Dhruva
Anand Dhruva
YCYvette P. Conley
Yvette P. Conley
RCRaymond J. Chan
Raymond J. Chan
CMChristine Miaskowski
Christine Miaskowski
Fatigue is the most common and debilitating symptom experienced by oncology patients undergoing chemotherapy. Little is known about patient characteristics that predict changes in fatigue severity ...

27 April 2024 in Cancer
Verified
Journal Article
Closed access
KOKate R. Oppegaard
Kate R. Oppegaard
SMSamantha J Mayo
Samantha J Mayo
TATerri Armstrong
Terri Armstrong
VDVasuda Dokiparthi
Vasuda Dokiparthi
MMMichelle Melisko
Michelle Melisko
KKKord M. Kober
Kord M. Kober